All In Biotech

Drug Trial Radar · NCT02573025

A Bioequivalence Study of Pegylated Interferon Alfa-2a (PEG-IFN Alfa-2a) Benzyl Alcohol (BA)-Free Formulation Versus PEG-IFN Alfa-2a (Pegasys) Following Subcutaneous Administration

An Open-Label, Randomized, Multi-Center, Single Dose, Two-Period, Two Sequence Crossover Study to Investigate the Bioequivalence of Peginterferon (PEG-IFN) Alfa-2a Benzyl Alcohol-Free Formulation Versus the Reference Market Formulation Following Subcutaneous Administration Via Prefilled Syringe in Healthy Chinese Subjects

Last checked: Nov 19, 2026Latest source record: Mar 13, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 277 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

277

Actual

Start

Sep 17, 2015

Primary completion

Apr 11, 2016

Study completion Apr 11, 2016

Sponsor

Lead sponsor
Hoffmann-La RocheRoche (Genentech) (RHHBY)
Sponsor type
Industry
First posted
Oct 9, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Crossover
Masking
None
Primary purpose
Basic science
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is an open-label, randomized, multi-center, single dose, two-period, two-sequence crossover study to investigate the bioequivalence of PEG-IFN alfa-2a BA-free formulation versus the reference market formulation (PEG-IFN alfa-2a \[Pegasys®\]) following subcutaneous administration via prefilled syringe in healthy Chinese participants.

Conditions

  • Healthy Volunteers

Interventions

  • PEG-IFN alfa-2a BA-free formulation (Test)Drug

    Participants will receive single injection of 180 micrograms (mcg) of PEG-IFN alfa-2a BA-free formulation, subcutaneously via prefilled syringe in either period 1 and 2 (each period having 35 days).

  • PEG-IFN alfa-2a market formulation (Reference)Drug

    Participants will receive single injection of 180 mcg of PEG-IFN alfa-2a market formulation, subcutaneously via prefilled syringe in either period 1 and 2 (each period having 35 days).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Maximum Observed Concentration (Cmax) for PEG-IFN alfa-2aTime frame: Predose (-1 Hour), Hour 1, 3, 5, 8, 12, 24, 48, 72, 84, 96, 120, 144, 168, 192, 216, 240, 312, 384, 480, 552, 648, 816 post Dose
  2. Area Under the Concentration-Time Curve (AUC) for PEG-IFN alfa-2a From Time Zero to 816 hours (AUC0-816h)Time frame: Predose (-1 Hour), Hour 1, 3, 5, 8, 12, 24, 48, 72, 84, 96, 120, 144, 168, 192, 216, 240, 312, 384, 480, 552, 648, 816 post Dose

Locations

9 sites in 5 countries. Site status is shown where the registry gives one.

  • CMAX A division of IDT Australia Limited

    Adelaide, South Australia, Australia

  • The University of Hong Kong; Pharmacy Clinical Trials

    Hong Kong, Hong Kong

  • The Chinese University of Hong Kong; Emergency Medicine

    Shatin, Hong Kong

  • Christchurch Clinical Studies Trust

    Christchurch, New Zealand

  • Auckland Clinical Studies Limited

    Grafton, New Zealand

  • SingHealth Investigational Medicine Unit; Haematology

    Singapore, Singapore

  • Changi General Hospital- Parent; Department of Rheumatology

    Singapore, Singapore

  • China Medical University Hospital;Oncology and Hematology Office Critical Care Center, 14H

    Taichung, Taiwan

  • Taipei Medical University Hospital; Clinical Research Center

    Taipei, Taiwan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.